⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer

Official Title: EXemestane in Progesterone and/or Estrogen Receptor Positive Epithelial Ovarian Cancer: A Randomized Phase III Trial, EXPERT

Study ID: NCT04460807

Conditions

Ovarian Cancer

Study Description

Brief Summary: In this Italian, multicenter, randomized, double-blind, placebo controlled, phase III study the efficacy of exemestane will be evaluated in addition to the standard front line treatment in patients with hormone-receptor-positive high grade serous or endometrioid Epithelian Ovarian Cancer (EOC). The patients enrolled in the EXPERT trial will receive exemestane or placebo in addition to standard treatment. Patients and investigators will be blinded to study treatment. The hypothesis underlying the proposed clinical trial is that exemestane added to standard first line therapy will significantly prolong median progression free survival (PFS).

Detailed Description: Estrogen and Progesterone play a role in promoting EOC growth, metastasis, and progression. Recent data show that ER and PgR expression is frequent in high grade EOC and has prognostic significance. A large meta-analysis showed a clinical benefit with any endocrine treatment, and in particular for aromatase inhibitors (AIs), with a greatere benefit for ER+ and/or PgR+ patients and platinum sensitive tumors. Moreover, the analysis of a few randomized clinical trials (RCTs) showed a reduced mortality with endocrine therapy in EOC, suggesting that ER and PgR have a predictive role and that inhibition of their activation could therefore be a treatment option for EOC. Exemestane is a well-tolerated and effective AI in endocrine sensitive breast cancer which inhibits the production of Estrogens by the adipose tissue in postmenopausal women. In this Italian, multicentre, randomized, double-blind, placebo controlled, phase III study will be assessed the efficacy of exemestane versus placebo in addition to the standard front line treatment in patients with high grade serous or endometrioid EOC, IHC positive (≥ 10%) ER or PgR disease, stage IIB - IV according to the FIGO classification. The primary objective of the study is to test the superiority of exemestane over placebo in addition to the standard front line treatment in terms of PFS. Secondary Objectives are: 1. to test whether the percent expression of ER and PgR is predictive of the effect of exemestane on PFS; 2. to test whether the addition of exemestane to the standard front line treatment can prolong Overall Survival (OS); 3. to evaluate objective response rate Overall Response Rate (ORR) of experimental treatment compared with the standard one; 4. to assess whether the effect of exemestane is affected by the proliferative index Ki67; 5. to evaluate the effect of exemestane on Quality of Life (QoL); 6. to evaluate the compliance to the study treatment; 7. to evaluate the safety profile of the experimental treatment compared with the standard one. Study design: a total of 468 subjects (234 per Arm) will be randomized in a 1:1 ratio to receive either standard chemotherapy treatment plus exemestane (Experimental arm) or standard chemotherapy plus placebo (Control arm). Exemestane/placebo will be self-administered as a single oral tablet of 25 mg/day until disease progression, unacceptable toxicity or physician/patient decision to withdraw, whichever comes first. Radiological disease assessments and CA125 will be performed at baseline and every 4 months from randomization, until end of study or disease progression whichever comes first. Safety assessments will be performed at each cycle during standard chemotherapy treatment, then at each study visit, up to 30 days after the last Experimental Treatment administration.Quality of Life will be assessed by a menopause-specific questionnaire, administered to patients at baseline (T0), at 12 months (T1) and at disease progression (T2). For patients who have signed the specific informed consent, tissues and blood samples will be collected.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

AO SS Antonio e Biagio e Cesare Arrigo, Alessandria, AL, Italy

Ospedale Oncologico IRCCS Bari, Bari, BA, Italy

Ospedale degli Infermi, Biella, BI, Italy

AULSS 1 Dolomiti - Ospedale "Santa Maria del Prato", Feltre, BL, Italy

Azienda Ospedaliero Universitaria Policlinico S.Orsola-Malpighi, Bologna, BO, Italy

ASST degli Spedali Civili di Brescia, Brescia, BS, Italy

Fondazione Poliambulanza, Brescia, BS, Italy

Ospedale di Manerbio, Manerbio, BS, Italy

AOU Cagliari, Policlinico Universitario, Cagliari, CA, Italy

Ospedale Policlinico "SS. Annunziata", Chieti, CH, Italy

Azienda Sanitaria Locale CN2, Alba, CN, Italy

Azienda Ospedaliera S.Croce e Carle, Cuneo, CN, Italy

Ospedale di Mondovì CN1, Mondovì, CN, Italy

Ospedale Sant Anna di Como, Como, CO, Italy

ARNAS Garibaldi, Catania, CT, Italy

Azienda Ospedaliera per l'emergenza Cannizzaro, Catania, CT, Italy

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, FC, Italy

Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy

ASL 3 Ospedale Villa Scassi, Genova, GE, Italy

IRCCS AOU San Martino - IST, Genova, GE, Italy

ASST Lecco - Ospedale "A. Manzoni", Lecco, LC, Italy

Ospedale "Vito Fazzi", Lecce, LE, Italy

UOS Oncologia Ginecologica, Ospedale S. Gerardo, Monza, MB, Italy

Presidio Ospedaliero Unico Av3, Macerata, MC, Italy

Istituto Europeo di Oncologia (IEO), Milano, MI, Italy

AOU Policlinico di Modena, Modena, MO, Italy

A.R.N.A.S. Ospedali Civico Di Cristina Benfratelli, Palermo, PA, Italy

Ospedale "Guglielmo da Saliceto", Piacenza, PC, Italy

Azienda Ospedaliero-Universitaria Pisana, Pisa, PI, Italy

CRO Centro di Riferimento Oncologico, Aviano, PN, Italy

Fondazione IRCCS Policlinico San Matteo, Pavia, PV, Italy

Azienda Ospedaliera Regionale San Carlo, Potenza, PZ, Italy

Ospedale "degli Infermi", Faenza, RA, Italy

Ospedale "Umberto I", Lugo, RA, Italy

Ospedale Santa Maria delle Croci, Ravenna, RA, Italy

Azienda Ospedaliera Arcispedale Santa Maria Nuova, Reggio Emilia, RE, Italy

Policlinico Umberto I, Università di Roma "La Sapienza", Roma, RM, Italy

Policlinico Universitario Fondazione Agostino Gemelli, Roma, RM, Italy

ASST Valtellina e Alto Lario, Sondrio, SO, Italy

Azienda Ospedaliero Universitaria di Sassari, Sassari, SS, Italy

Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo, TO, Italy

AO Ordine Mauriziano, Torino, TO, Italy

Azienda Ospedaliero-Universitaria Città della Salute e della Scienza - Ospedale Ostetrico Ginecologico Sant'Anna, Torino, TO, Italy

Presidio Ospedaliero S. Andrea, Vercelli, VC, Italy

Medical Oncology Division, Ente Ospedaliero Ospedali Galliera, Genova, , Italy

Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Napoli, , Italy

Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, , Italy

Contact Details

Name: Andrea DeCensi

Affiliation: E.O. Ospedali Galliera Genova

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: